<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01508156</url>
  </required_header>
  <id_info>
    <org_study_id>1894-001</org_study_id>
    <secondary_id>IDX-06A-001</secondary_id>
    <nct_id>NCT01508156</nct_id>
  </id_info>
  <brief_title>Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)</brief_title>
  <official_title>A Phase I/IIa Study Assessing Single and Multiple Doses of HCV NS5A Inhibitor IDX719 in Healthy and HCV-Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test the safety and tolerability of different doses of IDX719
      to find the best dose for future studies. The study will also assess the pharmacokinetics of
      IDX719. No formal hypotheses will be tested.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants experiencing an adverse event (AE)</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing serious AEs (SAEs)</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in HCV ribonucleic acid (RNA)</measure>
    <time_frame>Baseline and Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma drug concentration (Cmax)</measure>
    <time_frame>Pre-dose Day 1 to Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma drug concentration (Tmax)</measure>
    <time_frame>Pre-dose Day 1 to Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma drug concentration-time curve (AUC) from time zero to time of last measurable concentration (AUC0-t)</measure>
    <time_frame>Pre-dose Day 1 to Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero to time 24 hours (AUC0-24h)</measure>
    <time_frame>Pre-dose Day 1 to Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero to time infinity (AUC0-~)</measure>
    <time_frame>Pre-dose Day 1 to Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-dose trough plasma drug concentration (Ctrough)</measure>
    <time_frame>Pre-dose Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed terminal plasma drug concentration half-life (t1/2)</measure>
    <time_frame>Pre-dose Day 1 to Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent oral total plasma drug clearance (CL/F) as Dose/AUC0-~ (single dose) or Dose/AUC0-t (multiple doses)</measure>
    <time_frame>Pre-dose Day 1 to Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent oral total volume of distribution (Vz/F)</measure>
    <time_frame>Pre-dose Day 1 to Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount excreted in urine in each collection interval (Au)</measure>
    <time_frame>Pre-dose Day 1 to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative urine excretion (Au0-t)</measure>
    <time_frame>Pre-dose Day 1 to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of dose excreted in urine (% Dose excr)</measure>
    <time_frame>Pre-dose Day 1 to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal clearance (CLr)</measure>
    <time_frame>Pre-dose Day 1 to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing dose-limiting toxicity</measure>
    <time_frame>Up to 8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing graded laboratory abnormalities</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Group A: Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants take IDX719 (5 mg - 100 mg) or matching placebo by mouth as either 1 single dose or as 7 daily doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: HCV Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive participants infected with HCV genotype (GT) 1, GT2, or GT3 take IDX719 (1 mg - 100 mg) or matching placebo as either 1 single dose or as 7 daily doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX719</intervention_name>
    <description>IDX719 liquid suspension (1 - 100 mg) taken by mouth.</description>
    <arm_group_label>Group A: Healthy Participants</arm_group_label>
    <arm_group_label>Group B: HCV Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo liquid suspension matching IDX719 taken by mouth.</description>
    <arm_group_label>Group A: Healthy Participants</arm_group_label>
    <arm_group_label>Group B: HCV Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All Participants

          -  Is in good general health.

          -  Agrees to use double-barrier method of birth control for at least 90 days after the
             last dose of study drugs.

          -  HCV Participants

          -  Has documented GT1, GT2, or GT3 chronic HCV infection.

        Exclusion Criteria:

          -  All Participants

          -  Is pregnant or breastfeeding.

        HCV Participants

          -  Has received prior HCV treatment.

          -  Is co-infected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Vince B, Hill JM, Lawitz EJ, O'Riordan W, Webster LR, Gruener DM, Mofsen RS, Murillo A, Donovan E, Chen J, McCarville JF, Sullivan-BÃ³lyai JZ, Mayers D, Zhou XJ. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. J Hepatol. 2014 May;60(5):920-7. doi: 10.1016/j.jhep.2014.01.003. Epub 2014 Jan 14.</citation>
    <PMID>24434503</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2012</study_first_submitted>
  <study_first_submitted_qc>January 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2012</study_first_posted>
  <last_update_submitted>April 24, 2015</last_update_submitted>
  <last_update_submitted_qc>April 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>treatment-naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

